{"id":"W4405038597","doi":"10.1182/blood-2024-198424","title":"Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Rituximab; Oxaliplatin; Gemcitabine; Diffuse large B-cell lymphoma; Internal medicine; Refractory (planetary science); Oncology; Lymphoma; Chemotherapy; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004456046,0.0009826907,0.002025218,0.0004341247,0.0003661216,0.001032389,0.0006390151,0.0008035581,0.002391881],"category_scores_gemma":[0.002494539,0.0002830394,0.003323522,0.0005116999,0.0006291986,0.0007670416,0.0006003393,0.001728724,0.000510707],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007318632,"about_ca_system_score_gemma":0.0004694229,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005336694,"about_ca_topic_score_gemma":0.0009721919,"domain_scores_codex":[0.9985038,0.0008268161,0.0001211522,0.0002132899,0.0001838986,0.0001509855],"domain_scores_gemma":[0.9973356,0.0006218562,0.0009945349,0.0001631905,0.0002282118,0.0006566789],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7806169,0.008995896,0.1572138,0.00114829,0.01139348,0.0001186639,0.0001756014,0.002778683,0.004734868,0.0001411704,0.002853694,0.029829],"study_design_scores_gemma":[0.1380115,0.2036911,0.6384612,0.0001331038,0.009403109,0.0003223614,0.0002061925,0.002829537,0.003353297,0.0004905025,0.003002738,0.00009547633],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921179,0.002220628,0.0002497649,0.0001792379,0.00008081714,0.0004312854,0.003435777,0.00002301246,0.001261595],"genre_scores_gemma":[0.9939208,0.000391303,0.0002551574,0.0002728899,0.00007999106,0.0006196401,0.003963252,0.000007762761,0.0004892424],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004456046,"threshold_uncertainty_score":0.02356607,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009550830445306644,"score_gpt":0.2368935761899054,"score_spread":0.2273427457445988,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}